This article is more than 5 years old. Information may no longer be current.
Novaliq names new chief medical officer
Gabriela Burian, MD, MPH, has been named Novaliq’s new chief medical officer, according to a company press release.
Burian will lead Novaliq’s global clinical development and regulatory efforts, as well as expand the company’s proprietary ocular therapeutics pipeline, the release said.
She has more than 25 years of clinical experience, including leadership roles at Novartis Pharma and F. Hoffmann-La Roche.
“Novaliq has a very exciting and robust dry eye therapy pipeline and has the potential to address significant clinical needs in retina and glaucoma as well,” Burian said in the release.
Sonja Krösser, PhD, Novaliq’s vice president of preclinical and clinical development, will continue to be responsible for dry eye developments and the company's preclinical and clinical team.